Jasper TherapeuticsJSPR
JSPR
About: Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Employees: 45
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
141% more call options, than puts
Call options by funds: $3.39M | Put options by funds: $1.4M
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
16% more funds holding
Funds holding: 68 [Q2] → 79 (+11) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 21
1.31% less ownership
Funds ownership: 98.56% [Q2] → 97.24% (-1.31%) [Q3]
18% less capital invested
Capital invested by funds: $337M [Q2] → $275M (-$61.8M) [Q3]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q2] → 4 (-1) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$40
626%
upside
Avg. target
$55
903%
upside
High target
$70
1,170%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Silvan Tuerkcan 30% 1-year accuracy 17 / 56 met price target | 1,170%upside $70 | Market Outperform Reiterated | 10 Jan 2025 |
HC Wainwright & Co. Emily Bodnar 13% 1-year accuracy 19 / 150 met price target | 626%upside $40 | Buy Maintained | 10 Jan 2025 |
RBC Capital Gregory Renza 34% 1-year accuracy 29 / 86 met price target | 771%upside $48 | Outperform Maintained | 9 Jan 2025 |
BMO Capital Etzer Darout 22% 1-year accuracy 9 / 41 met price target | 1,043%upside $63 | Outperform Initiated | 6 Dec 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile
Neutral
GlobeNewsWire
2 weeks ago
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that Jasper will host a virtual webinar on Wednesday, January 8, 2025, to present preliminary data from the BEACON study of briquilimab in CSU.
Neutral
GlobeNewsWire
1 month ago
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that the first patient has been dosed in Jasper's Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN (Evaluating The Efficacy and Safety of briquilimab In participANts with allergic asthma). The ETESIAN study is evaluating a single administration of subcutaneous briquilimab in patients with asthma.
Positive
Seeking Alpha
2 months ago
Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma
Jasper Therapeutics, Inc.'s Briquilimab shows promise in treating chronic urticaria and asthma, with potential market approval by 2027, offering significant revenue opportunities in large, underserved markets. Despite positive preliminary clinical results, Jasper faces financial risks, needing additional funds by Q3 2025, which may lead to shareholder dilution. Analysts rate JSPR as a strong buy with a $69.5 target, but caution is advised due to the speculative nature and financial instability.
Neutral
GlobeNewsWire
2 months ago
Jasper Therapeutics to Participate at Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences:
Neutral
GlobeNewsWire
2 months ago
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended September 30, 2024, provided a corporate update and announced the closure of Jasper's legacy clinical study in lower-risk myelodysplastic syndromes (LR-MDS).
Neutral
GlobeNewsWire
2 months ago
Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting data from preclinical studies evaluating briquilimab at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24-28, 2024, in Boston, Massachusetts.
Positive
Benzinga
3 months ago
Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?
On Monday, Jasper Therapeutics Inc JSPR stock is trading higher after the company reported preliminary data from its ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria (ColdU) or symptomatic dermographism (SD).
Neutral
GlobeNewsWire
3 months ago
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved a complete response No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6 th , 2025, including 180mg Q8W cohort Company to host conference call and webinar today at 8:00 a.m. EDT REDWOOD CITY, Calif.
Neutral
GlobeNewsWire
4 months ago
Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma
REDWOOD CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that Health Canada has cleared the Company's Clinical Trial Application (CTA) for a Phase 1b/2a asthma challenge study evaluating briquilimab in asthma.
Charts implemented using Lightweight Charts™